İnflamasyon ve Depresyon

Abstract

Depresyon, birden fazla etkene bağlı olarak gelişip, bireylerin yaşam kalitesini önemli ölçüde etkileyen ve erken ölümle ilişkilendirilen ruhsal bir bozukluktur. Çağımızın en sık görülen hastalıklardan biri olan depresyonun birçok hastalıkla beraber seyrettiği, özellikle de yaygın olarak görülen kronik inflamatuvar hastalıklarla ilişkili olabileceğine dair birçok çalışma mevcuttur. Depresyon sırasında stres hormonları, sitokinler ve C-reaktif protein gibi biyokimyasal değerlerin değişimi, depresyon ile inflamatuvar yolaklar arasında bir ilişkinin varlığına işaret etmektedir. Yapılan klinik araştırmalarda, inflamasyon tedavisinde kullanılan bazı ilaçlar, akut depresif hastalarda tek başına ya da antidepresan tedaviye ilave olarak kullanıldığında, depresyon belirtilerinde azalma görülmüştür. Fakat bu çalışmaların büyük bir çoğunluğu akut depresyon vakalarında yapıldığından, kronik depresyon vakalarında antiinflamatuvarların kullanımına yönelik yeterli veri bulunmamaktadır. Depresyon ve inflamasyon arasındaki ilişki ile alakalı elde edilen deneysel ve klinik veriler, yeni ilaç geliştirilebilmesi ve her iki durumun patofizyolojik yolağının aydınlatılması açısından önem taşımaktadır. Bu derlemenin amacı, proinflamatuvar sitokinler ve depresyon arasındaki ilişkiyi literatürdeki güncel veriler ışığında değerlendirmektir.

Keywords

• Depresyon,inflamasyon,antiinflamatuvar ilaçlar,sitokin,CRP

Inflammation and Depression

Abstract

Depression is a mental disorder affects individuals’ quality of life which is depended on multiple factors and associated with early death. It is known that depression is one of the most common disease of the era and progressing with many diseases concomitantly, especially with chronical inflammatory disorders. Alterations in biochemical markers such as stress hormones, cytokines, C-reactive protein, etc. during depression indicate the existence of a relationship between depression and inflammatory pathways. In the clinical studies, some drugs used in the treatment of inflammation reported to lead to an improvement of depression symptoms in acute depressive patients when used alone or concomitant with the antidepressant treatment. However, a large majority of the studies in the literature has been based on the acute cases of depression. Therefore, there is no enough data for the clinical use of anti-inflammatory drugs in chronic depression treatment. Experimental and clinical data about the relationship between depression and inflammation are important in terms of development of new drugs and may be promising for the elucidation of the pathophysiological pathway in both cases. This review aims to evaluate the relationship between proinflammatory cytokines and depression by means of the current studies in literature.

Keywords

• Depression,inflammation,antiinflammatory drugs,cytokines,CRP

References

1. World Health Organization (WHO). Depression. Available from: http://www.who.int/mental_health/ management/depression/en/ [Accessed: 20 September 2016]
2. Pratt LA, Brody DJ, Gu Q. Antidepressant Use in Persons Aged 12 and Over: United States, 2005– 2008. NCHS Data Brief 2011, No. 76.
3. Leff-Gelman P, Mancilla-Herrera I, Flores-Ramos M, Cruz-Fuentes C, Reyes-Grajeda JP et al. The Immune System and the Role of Inflammation in Perinatal Depression. Neurosci. Bull 2016,32(4):398–420.
4. Laitinen ML, Lönnroos E, Bell JS, Lavikainen P, Sulkava R, Hartikainen S. Use of antidepressants among community-dwelling persons with Alzheimer’s disease: a nationwide register-based study. International Psychogeriatrics 2015, 27:4, 669–672.
5. Aydin N, Cetin M, Kurt E, Savas H, Acıkel C et al. A report by Turkish Association for Psychopharmacology on the Psychotropic Drug Usage in Turkey and Medical, Ethical and Economical Consequences of Current Applications. Bulletin of Clinical Psychopharmacology 2013, 23(4):390-402.
6. Durukan E, İlhan MN, Bumin MA, Aycan S. Postpartum Depression Frequency and Quality of Life Among a Group of Mothers Having a Child Aged 2 Weeks-18 Months. Balkan Med J 2011, 28: 385-393.
7. Keskinoğlu P, Pıçakçıefe M, Giray H, Bilgiç N, Uçku R, Tunca Z. Yaşlılarda depresif belirtiler ve risk etmenleri. Genel Tıp Derg 2006, 1: 21-26.
8. van Dooren FEP, Schram MT, Schalkwijk CG, Stehouwer CDA, Henry RMA et al. Associations of low grade inflammation and endothelial dysfunction with depression – The Maastricht Study. Brain, Behavior, and Immunity 2016, 56: 390–396.

9. Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: Depression Fans the Flames and Feasts on the Heat. AmJ Psychiatry 2015, 172:1075–1091.
10. Muthuramalingam A, Menon V, Rajkumar RP, Negi VR. Is Depression an Inflammatory Disease? Findings from a Cross-sectional Study at a Tertiary Care Center. Indian Journal of Psychological Medicine 2016, 38:114-119.
11. Maldonado-Bouchard S, Peters K, Woller SA, Madahian B, Faghihi U, Patel S, Bake S, Hook MA. Inflammation is increased with anxiety- and depression-like signs in a rat model of spinal cord injury. Brain, Behavior, and Immunity 2016, 51:176–195.
12. Song J, Kim E, Kim CH, Song HT and Lee JE. The role of orexin in post-stroke inflammation, cognitive decline, and depression. Molecular Brain 2015, 8:16.
13. Gümrü S, Arıcıoğlu F. Inflammation in Depression: The Role of Cytokines. MÜSBED 2012, 2(3):103-107.
14. Yanartaş Ö, Bıçakcı E, Şenkal Z, Karaman K, Türkkan A et al. İnflamatuar Barsak Hastalıklarında Ruhsal Belirtiler ve Yaşam Kalitesinin Değerlendirilmesi. Journal of Mood Disorders 2014, 4(3): 115-121.
15. Sözeri Varma G. Neuroinflammatory Hypothesis in Major Depressive Disorder. Current Approaches in Psychiatry 2014, 6(1):1-9.
16. Bolu A, Erdem M, Balıkcı A, Bilgen AE, Akgül EÖ et al. Majör Depresyon Hastalarında Atak Sayısı ile Serum Haptoglobulin ve Neopterin Düzeyleri Arasındaki İlişki. Journal of Mood Disorders 2013, 3(1):1-7.
17. Widner B, Laich A, Sperner-Unterweger B,Ledochowski M, Fuchsa D. Neopterin production, tryptophan degradation, and mental depression—What is the link? Brain, Behavior, and Immunity 2002, 16:590–595.
18. Lee YA, Kang SG, Kim SH, Park SJ, Kim HN et al. Assessment of Lifestyle Effects on the Levels of Free Oxygen Radicals in the Korean Population. Korean J Fam Med 2012, 33:296-304.
19. Sahin C, Dursun S, Cetin M, Aricioglu F. The Neuroinflammation Perspective of Depression: Reuniting the Outstanding Mechanisms of the Pathophysiology. Bulletin of Clinical Psychopharmacology 2016, 26(2):196-206.
20. Köhler O, Petersen L, Mors O, Gasse C. Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain and Behavior 2015, 5(8): e00338,doi: 10.1002/brb3.338.
21. Lai JS, Oldmeadow C, Hurea A, McEvoya M, Hiles SA et al. Inflammation mediates the association between fatty acid intake and depression in oldermen and women. Nutrition Research 2016, 36: 234-245.
22. Raison CL, Miller AH. Is Depression an Inflammatory Disorder? Curr Psychiatry Rep 2011, 13:467–475.
23. Krishnadas R, Nicol A, Sassarini J, Puri N, Burden AD et al. Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. Brain, Behavior, and Immunity 2015, 51:29-38.
24. Savcı V. Antidepresan İlaçların Farmakolojik Özellikleri, J Int Med Sci, 2(1):22-31, 2006.
25. Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology 2016, 233:1575–1589.
26. Ramirez K, Sheridan JF. Antidepressant imipramine diminishes stress-induced inflammation in the periphery and central nervous system and related anxiety- and depressive- like behaviors. Brain Behav Immun 2016,57:293-303.
27. Koç F, Süleyman H, Polat B. The Anti-inflammatory Activity of Antidepressant Drugs in Rats. The Eurasian Journal of Medicine 2007, 39:169-172.
28. Guarneri F, Guarneri C, Marini HR. Amitriptyline and bromazepam in the treatment of vibratory angioedema: which role for neuroinflammation? Dermatologic Therapy 2014, 27: 361–364.
29. Uher R, Tansey KE, Dew T, Maier W, Mors O. An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. Am J Psychiatry 2014, 171:1278–1286.
30. Vavilova T, Ostrovskaya I, Axenova L, Buneeva O, Medvedev A et al. Monoamine oxidase and semicarbazide sensitive amine oxidase activities in normal and inflamed human dental pulp. Med Sci Monit 2009, 15(10):289-292.
31. Chung HS, Kim H, Bae H. Phenelzine (Monoamine Oxidase Inhibitor) Increases Production of Nitric Oxide and Proinflammatory Cytokines via the NF-Jb Pathway in Lipopolysaccharide- Activated Microglia Cells. Neurochem Res 2012, 37:2117–2124.
32. Spector WG, Willoughby DA. Suppression of increased capillary permeability in injury by monoamine oxidase inhibitors. Nature 1960, (9)186:162-3.
33. Rx Media Pharma®, International drug database, 2016.
34. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Fluoxetine and Citalopram Exhibit Potent Antiinflammatory Activity in Human and Murine Models of Rheumatoid Arthritis and Inhibit Toll-like Receptors. Arthritis & Rheumatism 2010, 62(3):683–693.
35. Nazimek K, Strobel S, Bryniarski P, Kozlowski M, Filipczak-Bryniarski I, Bryniarski K. The role of macrophages in anti-inflammatory activity ofantidepressant drugs. Immunobiology 2016, doi: 10.1016/j.imbio.2016.07.001.
36. Kao CY, He Z, Zannas AS, Hahn O, Kühne C, Reichel JM et al. Fluoxetine treatment prevents the inflammatory response in a mouse model of posttraumatic stress disorder. J Psychiatr Res 2016, 76:74-83.
37. Sluzewska A, Rybakowski J, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicv K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. NY Acad. Sci 1995,762 (1):474–47.
38. Coccaro EF, Lee R, Breen EC, Irwin MR. Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder. Psychiatry Res 2015, 229(3):844-9.
39. Bortolato B, Carvalho AF, Soczynska JK, Perini GI, McIntyre RS. The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Current Neuropharmacology 2015, 13:558-576.
40. Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinejad P, Ghaleiha A, Akhondzadeh S. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo controlled trial. Bipolar Disord 2015, 17: 606–614.
41. Majd M, Hashemian F, Hosseini SM, Vahdat Shariatpanahi M, Sharifi A. A Randomized, Double- blind, Placebo-controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-naive Depressed Women: A Pilot Study. Iran J Pharm Res 2015, 14(3):891-9.
42. Ayorech Z, Tracy DK, Baumeister D, Giaroli G. Taking the fuel out of the fire: Evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. Journal of Affective Disorders 2015,174:467–478.
43. Bhatt S, Shukla P, Raval J, Goswami S. Role of Aspirin and Dexamethasone against Experimentally Induced Depression in Rats. Basic & Clinical Pharmacology & Toxicology 2016, 119:10–18.
44. Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, Mansur RB, Brietzke E, Goldstein BI, McIntyre RS. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord 2016, 18: 89–101.
45. Bhatt S, Kilambi P, Patel P, Patel N, Panchal A, Shah G, Goswami S. Beneficial effect of aspirin against interferon-α-2b - induced depressive behavior in Sprague Dawley rats. Clin Exp Pharmacol Physiol. 2016, doi: 10.1111/1440-1681.12660.
46. Ghanizadeh A, Hedayati A. Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial. Anti-Inflammatory and Anti- Allergy Agents in Medicinal Chemistry 2014,13(2):108-111.
47. Baune BT. Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation? Curr Top Behav Neurosci 2016, doi:10.1007/7854_2016_19.
48. Meyer, JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin. Pharmacol. Ther 2012, 91:201–214.
49. Fleming P , Roubille C, Richer V, Starnino T, McCourt C. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. Journal of European Academy of Dermatology and Venereology 2015, 29:1063–1070.
50. Fu XY, Li HY, Jiang QS, Cui T, Jiang XH et al. Infliximab ameliorating depression-like behavior through inhibiting the activation of the IDO–HAAO pathway mediated by tumor necrosis factor-α in a rat model. Neuro Report 2016, 27:953–959.
51. Baune BT. Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention? Curr Opin Psychiatry 2015, 28(2):148-54.